CA2422309A1 - Selection of markers - Google Patents

Selection of markers Download PDF

Info

Publication number
CA2422309A1
CA2422309A1 CA002422309A CA2422309A CA2422309A1 CA 2422309 A1 CA2422309 A1 CA 2422309A1 CA 002422309 A CA002422309 A CA 002422309A CA 2422309 A CA2422309 A CA 2422309A CA 2422309 A1 CA2422309 A1 CA 2422309A1
Authority
CA
Canada
Prior art keywords
portfolio
gene
expression
relationship
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002422309A
Other languages
English (en)
French (fr)
Inventor
Tim Jatkoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Clinical Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2422309A1 publication Critical patent/CA2422309A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)
CA002422309A 2002-03-29 2003-03-28 Selection of markers Abandoned CA2422309A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36879002P 2002-03-29 2002-03-29
US60/368,790 2002-03-29

Publications (1)

Publication Number Publication Date
CA2422309A1 true CA2422309A1 (en) 2003-09-29

Family

ID=27805329

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002422309A Abandoned CA2422309A1 (en) 2002-03-29 2003-03-28 Selection of markers

Country Status (10)

Country Link
US (2) US20030194734A1 (enExample)
EP (1) EP1349104A3 (enExample)
JP (1) JP2004163388A (enExample)
KR (1) KR20030078803A (enExample)
CN (1) CN1495272A (enExample)
AR (1) AR039212A1 (enExample)
AU (1) AU2003203529A1 (enExample)
BR (1) BR0303080A (enExample)
CA (1) CA2422309A1 (enExample)
MX (1) MXPA03002865A (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1788083A4 (en) * 2004-08-02 2008-08-13 Banyu Pharma Co Ltd METHOD FOR THE ADOPTION OF MEDICAMENT SENSITIVITY AGAINST THE INHIBITOR CDK4
WO2006060653A2 (en) * 2004-11-30 2006-06-08 Veridex Llc Lung cancer prognostics
JP2008528024A (ja) * 2005-01-31 2008-07-31 ディジタルジェノミクスインコーポレーション 肺癌診断用マーカー遺伝子
KR100690250B1 (ko) * 2005-01-31 2007-03-12 디지탈 지노믹스(주) 폐암 진단용 마커
US20070037186A1 (en) 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
IL177006A0 (en) 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
US20070207467A1 (en) 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
US20080058432A1 (en) * 2006-03-03 2008-03-06 Yixin Wang Molecular assay to predict recurrence of Duke's B colon cancer
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
SG144111A1 (en) * 2006-12-22 2008-07-29 Shares Advisors Llc X Portfolio selection for custom indices of public securities based on state of domicile of issuing company
US20080206777A1 (en) 2007-02-27 2008-08-28 Nuclea Biomarkers, Llc Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors
US20090192045A1 (en) * 2008-01-22 2009-07-30 Yuqiu Jiang Molecular staging of stage ii and iii colon cancer and prognosis
US20110059464A1 (en) 2008-04-08 2011-03-10 Muraca Patrick J Biomarker Panel For Prediction Of Recurrent Colorectal Cancer
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
CA2743211A1 (en) 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US9206482B2 (en) 2009-04-29 2015-12-08 Genomedx Biosciences Inc. Systems and methods for expression-based classification of thyroid tissue
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
AU2018310987A1 (en) 2017-08-04 2020-02-27 Decipher Biosciences, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1000347B (el) * 1988-12-21 1992-06-25 Ortho Diagnostic Systems Inc Μεθοδος παραγωγης νουκλεοτιδικων ανιχνευτων χρησιμοποιωντας ενα συμπληρωμα γεφυρωσεως.
US6350576B1 (en) * 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
US6275814B1 (en) * 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) * 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6882990B1 (en) * 1999-05-01 2005-04-19 Biowulf Technologies, Llc Methods of identifying biological patterns using multiple data sets
US6401043B1 (en) * 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
US6175824B1 (en) * 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
CA2375943A1 (en) * 1999-07-15 2001-01-25 Research Development Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof

Also Published As

Publication number Publication date
EP1349104A3 (en) 2004-01-02
US20030194734A1 (en) 2003-10-16
CN1495272A (zh) 2004-05-12
JP2004163388A (ja) 2004-06-10
US20100009371A1 (en) 2010-01-14
MXPA03002865A (es) 2004-08-11
EP1349104A2 (en) 2003-10-01
AU2003203529A1 (en) 2003-10-23
BR0303080A (pt) 2004-02-17
KR20030078803A (ko) 2003-10-08
AR039212A1 (es) 2005-02-09

Similar Documents

Publication Publication Date Title
US7348142B2 (en) Cancer diagnostic panel
US20100009371A1 (en) Selection of markers
Pentheroudakis et al. Cancer of unknown primary site: missing primary or missing biology?
JP6824923B2 (ja) 胃腸癌での増殖の徴候及び予後
Larsen et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma
Singh et al. Gene expression correlates of clinical prostate cancer behavior
Van't Veer et al. Gene expression profiling predicts clinical outcome of breast cancer
KR101530689B1 (ko) 직장결장암용 예후 예측
Knudsen et al. Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens
JP6404304B2 (ja) メラノーマ癌の予後予測
US20200190597A1 (en) Identification of tumors
US20060195266A1 (en) Methods for predicting cancer outcome and gene signatures for use therein
CA2905620A1 (en) Neuroendocrine tumors
JP2004537261A (ja) 候補遺伝子のアレイを用いた原発性乳がんの遺伝子発現プロファイリング
Goldsmith et al. The microrevolution: applications and impacts of microarray technology on molecular biology and medicine
Sok et al. Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis
Miller et al. Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine
US7473526B2 (en) Breast cancer prognostic portfolio
Van der Vegt et al. Microarray methods to identify factors determining breast cancer progression: potentials, limitations, and challenges
EP3722444A1 (en) Method for determining rcc subtypes
WO2005083128A2 (en) Methods for predicting cancer outcome and gene signatures for use therein
Busam Ancillary Molecular Tests for the Diagnosis of Melanocytic Tumors
EP1679382A2 (en) Panel of nucleic acid sequences for cancer diagnosis
Goodison Gene expression profiling of breast cancer in ethnic populations: an aid to gene discovery for the benefit of all
Van Laar Optimisation of CDNA Microarray Tumour Profiling and Molecular Analysis of Epithelial Ovarian Cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20100329